Amgen Stock News

A few big biopharma names were on the move Tuesday morning, and analysts are taking their shot at them.

This article was originally published on TipRanks.com Biopharmaceutical company Amgen Inc. The post Amgen Reports Mixed Q4 Results appeared first on Smarter Analyst .

If any investor has stood the test of time, it is Warren Buffett. For years, the “Oracle of Omaha” has had a rock-star-like presence in the investing world His annual Berkshire Hathaway shareholde

Amgen Inc's  AMGN Q4 revenues increased 3% Y/Y to $6.84 billion, slightly missing the consensus of $6.88 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Amgen saw its net income in Q4 2021 rise ~18% compared to the prior-year period even as product review remained virtually flat.

Shares of Amgen Inc. rose more than 3% in the extended session Monday after the drug maker reported an adjusted quarterly profit above Wall Street expectations and said sales rose in part due to COVID-19 products. Amgen said it earned $1.9 billion, or $3.36 a share, in the quarter, compared with $1.6 billion, or $2.76 a share, in the year-ago quarter. Adjusted for one-time items, Amgen earned $4.36 a share. Sales rose 3% to $6.8 billion, thanks in part to a revenue bump from its collaboration with Eli Lilly & Co. on COVID-19-related products, Amgen said. In addition, volumes grew double-digits for several products such as osteoporosis drug Prolia and high-cholesterol treatment Repatha, Amgen said. Growth in these and other products "combined with our many pipeline opportunities, position us well for long-term growth," Chief Executive Robert A. Bradway said in a statement. FactSet consensus called for earnings of $4.04 a share on sales of $6.9 billion. Amgen stock ended the regular trading day up 0.6%.

https://www.investing.com/news/stock-market-news/amgen-earnings-beat-revenue-misses-in-q4-2758744

Amgen press release (AMGN): Q4 Non-GAAP EPS of $4.36 beats by $0.35.Revenue of $6.85B (+3.3% Y/Y) misses by $20M.Revenue from the Eli Lilly and Company (Lilly) COVID-19…

Amgen reported soaring quarterly earnings Monday, but sales didn''t inch up enough to top expectations likely leaving Amgen stock in limbo.

THOUSAND OAKS, Calif., Feb. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results include: For the fourth quarter, total revenues increased 3% to $6.8 billion in comparison to

After Monday's close, more companies reported earnings results, including Amgen, TakeTwo Interactive and Chegg.

Amgen (AMGN) delivered earnings and revenue surprises of 5.31% and 0.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amgen Inc''s (NASDAQ: AMGN ) short percent of float has risen 5.91% since last its last report. The company recently reported that it has 12.07 million shares sold short , which is 2.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.3 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price Full story available on Benzinga.com

Shares of Amgen Inc. (NASDAQ: AMGN) stepped higher following the release of its Q4 earnings report showing an EPS beat and a slight miss on sales. The company reported, on a GAAP basis, a 2% decrease

Shares of Amgen Inc. AMGN, +0.64% rose more than 3% in the extended session Monday after the drug maker reported an adjusted quarterly profit above Wall Street expectations and said sales rose in part